Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « biologic »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
biogenesis < biologic < biological  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 33.
[0-20] [0 - 20][0 - 33][20-32][20-40]
Ident.Authors (with country if any)Title
000023 (2020) Yehyun Park [Corée du Sud] ; Jae Hee Cheon [Corée du Sud]Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
000029 (2020) Sara Benchérifa ; Bouchra Amine ; Imane El Binoune ; Samira Rostom ; Rachid BahiriTwo cases of perforated corneal ulcers complicating rheumatoid arthritis treated successfully by biological therapy
000047 (2020) María Martín-L Pez [Espagne] ; Eliseo Albert [Espagne] ; Mario Fernández-Ruiz [Espagne] ; Isidoro González-Álvaro [Espagne] ; Esther Rodríguez [Espagne] ; José M. Aguado [Espagne] ; David Navarro [Espagne] ; José L. Pablos [Espagne]Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies.
000118 (2020) Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000151 (2020) Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000164 (2020) Giulia Cassone ; Andreina Manfredi ; Fabiola Atzeni ; Vincenzo Venerito ; Caterina Vacchi ; Valentina Picerno ; Federica Furini ; Gian Luca Erre ; Paola Tomietto ; Anna Laura Fedele [Italie] ; Giovanni Della Casa [Italie] ; Valeria Nucera ; Chiara Giannitti [Italie] ; Carlo Salvarani ; Marco SebastianiSafety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
000169 (2020) Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie]Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
000197 (2020) Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000204 (2020) Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Lenore Tominna [États-Unis] ; Ibrahim Abbass [États-Unis]Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
000205 (2020) Karin Luttropp [Suède] ; Johan Dalén [Suède] ; Axel Svedbom [Suède] ; Mary Dozier [États-Unis] ; Christopher M. Black [États-Unis] ; Amy Puenpatom [États-Unis]Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review
000206 (2020) Christos Koutsianas ; Konstantinos Thomas ; Dimitrios VassilopoulosReactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
000216 (2020) Elaheh Kordzadeh-Kermani [Iran] ; Hossein Khalili [Iran] ; Iman Karimzadeh [Iran] ; Mohammadreza Salehi [Iran]Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators
000218 (2020) Piero Ruscitti [Italie] ; Paola Cipriani [Italie] ; Vasiliki Liakouli [Italie] ; Daniela Iacono [Italie] ; Ilenia Pantano [Italie] ; Francesco Caso [Italie] ; Federico Perosa [Italie] ; Fabiola Atzeni [Italie] ; Francesco Paolo Cantatore [Italie] ; Raffaele Scarpa [Italie] ; Francesco Ciccia [Italie] ; Roberto Giacomelli [Italie]Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
000244 (2020) Przemysław Błyszczuk [Suisse, Pologne] ; Zoltan Szekanecz [Hongrie]Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis
000258 (2020) Peter N. Taylor [Royaume-Uni] ; Lei Zhang [Royaume-Uni] ; Richard W J. Lee [Royaume-Uni] ; Ilaria Muller [Royaume-Uni] ; Daniel G. Ezra [Royaume-Uni] ; Colin M. Dayan [Royaume-Uni] ; George J. Kahaly [Allemagne] ; Marian Ludgate [Royaume-Uni]New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
000259 (2020) Sara Pagani [Royaume-Uni] ; Mattia Bellan [Italie] ; Daniele Mauro [Royaume-Uni] ; Luigi Mario Castello [Italie] ; Gian Carlo Avanzi [Italie] ; Myles J. Lewis [Royaume-Uni] ; Pier Paolo Sainaghi [Italie] ; Costantino Pitzalis [Royaume-Uni] ; Alessandra Nerviani [Royaume-Uni]New Insights into the Role of Tyro3, Axl, and Mer Receptors in Rheumatoid Arthritis
000286 (2020) Tiago Torres [Portugal] ; Luis Puig [Espagne]Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
000307 (2020) Ethan S. Sen [Royaume-Uni] ; A V Ramanan [Royaume-Uni]Juvenile idiopathic arthritis-associated uveitis.
000311 (2020) Durga Prasanna Misra [Inde] ; Sakir Ahmed [Inde] ; Vikas Agarwal [Inde]Is biological therapy in systemic sclerosis the answer?
000324 (2020) Sae Ochi [Japon] ; Kazuyoshi Saito [Japon] ; Fumitaka Mizoguchi [Japon] ; Shigeaki Kato [Japon] ; Yoshiya Tanaka [Japon]Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
000378 (2020) Lianne Kearsley-Fleet [Royaume-Uni] ; Eleanor Heaf [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Eileen Baildam [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni] ; Helen E. Foster [Royaume-Uni] ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "biologic" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "biologic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    biologic
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021